Concepedia

Author

Ming‐Dauh Wang

Eli Lilly (United States)

Also Known As

Ming-Dauh Wang, Ming‐Dauh Wang

25

Publications

391

Citations

8

H-Index

6

Concepts

All Affiliations

Eli Lilly (United States)
MW

About

Ming‐Dauh Wang is an author at Eli Lilly (United States) specializing in patient safety, time-varying confounding, and clinical trials.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

11

2

Clinical Trials

1

1

11

3

Marginal Structural Models

1

1

11

4

Statistics

1

1

11

5

Time-varying Confounding

1

1

11

Ming‐Dauh Wang

×

8

Publications

341

Citations

8

H-Index

YearCitations

Bayesian predictive approach to interim monitoring in clinical trials

Alexei Dmitrienko, Ming‐Dauh Wang

Statistics in Medicine

2005

128

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study

John J.P. Kastelein, Steven E. Nissen, Daniel J. Rader,

European Heart Journal

2016

76

Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome

John S. Millar, Danielle Duffy, Ramprasad Gadi,

Arteriosclerosis Thrombosis and Vascular Biology

2008

42

Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults

Jeffrey G. Suico, Ming‐Dauh Wang, Stuart Friedrich,

Journal of Pharmacy and Pharmacology

2014

34

Sample Size Reestimation by Bayesian Prediction

Ming‐Dauh Wang

Biometrical Journal

2007

28

CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: <i>in vitro</i> prediction and clinical outcome

Ellen A. Cannady, Jeffrey G. Suico, Ming‐Dauh Wang,

British Journal of Clinical Pharmacology

2015

12

An evaluation of the trimmed mean approach in clinical trials with dropout

Ming‐Dauh Wang, Jiajun Liu, Geert Molenberghs,

Pharmaceutical Statistics

2018

11

Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong <scp>CYP</scp>3A and <scp>CYP</scp>2C8 inhibitors

Ellen A. Cannady, Ming‐Dauh Wang, Stuart Friedrich,

Pharmacology Research & Perspectives

2015

10

Page 1